The Government has launched a new long-acting HIV prevention injection known as (LEN PrEP), becoming one of the pilot states selected for the programme in Nigeria.
The injectable antiretroviral drug is administered once every six months and is designed to help prevent HIV infection, particularly among people considered at substantial risk.
Speaking during the launch at General Hospital Ezzangbo in Ohaukwu Local Government Area, the Ebonyi State Commissioner for Health, , described the innovation as a major breakthrough in HIV prevention.
According to him, the twice-yearly injection offers an alternative to the daily oral pre-exposure prophylaxis (PrEP) medication, which many users struggle to take consistently.
“HIV remains a public health concern, especially among young people in an already vulnerable population,” Ekuma said.
He noted that challenges such as stigma and poor adherence to daily medication had continued to affect HIV prevention efforts in the state.
The commissioner clarified that Lenacapavir is not intended to replace existing prevention methods but to complement them.
“This innovation is part of comprehensive prevention strategies such as testing, condom usage, behavioural interventions and treatment services,” he explained.
Ekuma also thanked the Coordinating Minister of Health and Social Welfare, , and the for selecting Ebonyi as one of the pilot states for the rollout.
The Permanent Secretary of the state Ministry of Health, , described the injection as a “game changer” capable of improving treatment adherence and reducing stigma associated with HIV prevention.
Similarly, the Director of Public Health in the ministry, , urged residents — especially people at higher risk of HIV infection — to take advantage of the programme.
The State AIDS Programme Coordinator, , said the injection would initially be available at eight designated health facilities across the state.
These include the , General Hospital Ezzangbo, General Hospital Onueke, and the Community facility.
Nigeria officially introduced Lenacapavir on March 31, 2026, with support from global health partners as part of efforts to reduce new HIV infections and strengthen the country’s HIV response strategy.
Other states selected for the pilot programme include , , , , , , and the .
